ALLO-501 ALPHA Study Design (Allogene-Sponsored)

ALLO-501 and ALLO-647 Phase 1 Study Overview

- Eligible patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma and:
  - Failed at least two prior lines of therapy
  - No prior anti-CD19 therapy
  - Absence of pre-existing donor (product)-specific anti-HLA antibodies
- Objectives:
  - Primary: Safety, tolerability and recommended P2 doses for ALLO-501 and ALLO-647
  - Secondary: Anti-tumor activity, ALLO-501 cellular kinetics, ALLO-647 PK, immunogenicity and host lymphocyte reconstitution
- Dose-escalation of ALLO-501: 40 to 360 x 10^6 CAR+ cells in 3+3 design
- Up to 24 patients



Treatment:
- Starting cell dose: 40 X 10^6 CAR+ cells

Lymphodepletion:
- ALLO-647: 13 mg/d x 3 days
- Fludarabine: 30 mg/m^2/d x 3 days
- Cyclophosphamide: 300 mg/m^2/d x 3 days

Servier holds ex-US rights to ALLO-501

Allogene THERAPEUTICS